Prostate Cancer with Bone Metastases
📧 Sign up to get email alerts when something new happens for Prostate Cancer with Bone Metastases.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-10-29FDA Approved: WYOST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for WYOST (denosumab) submitted by Sandoz Inc, expanding the product's indications.
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This clinical trials update describes an expanded access protocol for SL-28 in patients with advanced solid tumors and lists eligible condit…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 [Phase 2]
This is a Phase 2 trial evaluating 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. The study is currently re…
-
CLINICAL_TRIALS trial_result · 2024-11-29Clinical Trial Update: Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone [Phase 2]
Phase 2 study evaluating fluciclovine F-18 PET/CT imaging to assess bone metastases in hormone-naive men with prostate cancer; the trial has…
-
CLINICAL_TRIALS other · 2024-05-28Clinical Trial Update: Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
This clinical trials entry outlines the OLIGOMET study on local treatment outcomes for oligometastatic prostate cancer diagnosed via PSMA PE…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone [Phase 2]
Phase 2 trial update evaluating radium-223 dichloride with radiotherapy in hormone-naïve men with oligometastatic prostate cancer to bone; r…
-
FDA approval · 2023-03-07FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for zoledronic acid submitted by Mylan Institutional LLC.
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for Zoledronic acid from Dr. Reddy's Laboratories Limited, authorizing a generic product through…
-
CLINICAL_TRIALS trial_result · 2017-03-06Clinical Trial Update: Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis [Phase 4]
Phase 4 trial update assessing the efficacy, tolerability, and pharmacoeconomic impact of zoledronic acid in prostate cancer with bone metas…
-
CLINICAL_TRIALS trial_result · 2015-10-16Clinical Trial Update: Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases [Phase 3]
This clinical trial update reports the completion of a Phase 3 study evaluating androgen blockade therapy with or without zoledronic acid in…
-
FDA label_change · 2015-10-08FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA supplemental application for Zoledronic Acid submitted by Sagent Pharmaceuticals to modify the drug's labeling.
-
FDA approval · 2015-09-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for zoledronic acid from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2014-02-28Clinical Trial Update: Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques [NA]
This completed study evaluated magnetic resonance imaging and nuclear medicine techniques for imaging bone metastases in patients with prost…
-
FDA approval · 2013-03-04FDA Approved: ZOLEDRONIC ACID — Original Application (Mylan Institutional LLC)
FDA approved an original application for a zoledronic acid generic product manufactured by Mylan Institutional LLC.